2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 612

Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial
Abstract Number: 613

Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Abstract Number: 614

Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study
Abstract Number: 615

Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Abstract Number: 616

ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Abstract Number: 617

Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs
Abstract Number: 618

Do Canadian Rheumatologists Actually Treat to Target Once a Biologic Has Been Initiated? an Analysis from a Prospective, Observational Registry
Abstract Number: 619

Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Abstract Number: 620

Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Abstract Number: 621

Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Abstract Number: 622

Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study
Abstract Number: 623

WITHDRAWN
Abstract Number: 624

Association Between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis
Abstract Number: 625

Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis
Abstract Number: 626

Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].